Zine News

ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204

NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204. 

Publicaciones relacionadas

Botón volver arriba